EFSD and Novo Nordisk A/S Partnership for Diabetes Research in Europe

THE EFSD/NOVO NORDISK PARTNERSHIP FOR DIABETES RESEARCH IN EUROPE PROGRAMME WILL ACCEPT APPLICATIONS FROM ALL FIELDS OF DIABETES RESEARCH AND INCLUDING BOTH BASIC AND CLINICAL RESEARCH

Objecte

The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries.

Termini IISPV

Declaration of interest: IISPV’s deadline: January 20th, 2014(europa@iispv.cat)

Full proposal: IISPV’s deadline: January 27th, 2014

Termini Oficial

Deadline for submission of applications: 1 February 2014

Estàs interessat?

Omple el següent formulari per rebre més informació: